Grace Therapeutics, Inc.
NCM: GRCELive Quote
📈 ZcoreAI Score
Our AI model analyzes Grace Therapeutics, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get GRCE Z-Score →About Grace Therapeutics, Inc.
Healthcare
Biotechnology
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to improve neurological symptoms of Ataxia-Telangiectasia (A-T) and GTX-101, a topical bioadhesive film-forming polymer for the treatment of pain associated with postherpetic neuralgia (PHN). The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. Grace Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
📊 Fundamental Analysis
Grace Therapeutics, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -10.2%, which indicates that capital utilization is currently under pressure.
At a current price of $3.59, GRCE currently sits at the 50th percentile of its 52-week range (Range: $1.98 - $5.18).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Return on Equity
Weak
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$55.55M
Trailing P/E
--
Forward P/E
-5.64
Beta (5Y)
0.69
52W High
$5.18
52W Low
$1.98
Avg Volume
414K
Day High
Day Low